Two Weight-Loss Drug Giants Vie for China Market: Oral Semaglutide for Weight Management Accepted for Domestic Listing Application

Novo Nordisk's oral semaglutide tablet for weight management, the world's first approved oral GLP-1 receptor agonist for weight control, has been launched in multiple countries. Meanwhile, Eli Lilly's oral small-molecule GLP-1 drug orforglipron has submitted a listing application in China and is expected to gain approval within the year. Compared with injectables, oral medications overcome the barriers of needle phobia and cold-chain storage, significantly broadening the patient base.